Escherichia coli: development of carbapenem resistance during therapy.

Tao Hong, Ellen Smith Moland, Baha Abdalhamid, Nancy D. Hanson, Jie Wang, Cindy Sloan, Diane Fabian, Awny Farajallah, Jerome Levine, Kenneth S. Thomson

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Original languageEnglish (US)
Pages (from-to)e84-86
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number10
StatePublished - May 15 2005
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Escherichia coli: development of carbapenem resistance during therapy.'. Together they form a unique fingerprint.

Cite this